These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 36960789)

  • 1. The dark side of lipid metabolism in prostate and renal carcinoma: novel insights into molecular diagnostic and biomarker discovery.
    di Meo NA; Lasorsa F; Rutigliano M; Milella M; Ferro M; Battaglia M; Ditonno P; Lucarelli G
    Expert Rev Mol Diagn; 2023 Apr; 23(4):297-313. PubMed ID: 36960789
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic and Lipidomic Reprogramming in Renal Cell Carcinoma Subtypes Reflects Regions of Tumor Origin.
    Schaeffeler E; Büttner F; Reustle A; Klumpp V; Winter S; Rausch S; Fisel P; Hennenlotter J; Kruck S; Stenzl A; Wahrheit J; Sonntag D; Scharpf M; Fend F; Agaimy A; Hartmann A; Bedke J; Schwab M
    Eur Urol Focus; 2019 Jul; 5(4):608-618. PubMed ID: 29452772
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of metabolomics-derived biomarkers to identify renal cell carcinoma: a comprehensive perspective of the past ten years and advancements.
    Gupta A; Nath K; Bansal N; Kumar M
    Expert Rev Mol Diagn; 2020 Jan; 20(1):5-18. PubMed ID: 31825678
    [No Abstract]   [Full Text] [Related]  

  • 4. Revealing potential lipid biomarkers in clear cell renal cell carcinoma using targeted quantitative lipidomics.
    Li W; Wang X; Zhang X; Gong P; Ding D; Wang N; Wang Z
    Lipids Health Dis; 2021 Nov; 20(1):160. PubMed ID: 34774030
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integration of lipidomics and transcriptomics unravels aberrant lipid metabolism and defines cholesteryl oleate as potential biomarker of prostate cancer.
    Li J; Ren S; Piao HL; Wang F; Yin P; Xu C; Lu X; Ye G; Shao Y; Yan M; Zhao X; Sun Y; Xu G
    Sci Rep; 2016 Feb; 6():20984. PubMed ID: 26865432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipidomics applications for discovering biomarkers of diseases in clinical chemistry.
    Zhao YY; Cheng XL; Lin RC
    Int Rev Cell Mol Biol; 2014; 313():1-26. PubMed ID: 25376488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolomics and Metabolic Reprogramming in Kidney Cancer.
    Weiss RH
    Semin Nephrol; 2018 Mar; 38(2):175-182. PubMed ID: 29602399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolomic insights into pathophysiological mechanisms and biomarker discovery in clear cell renal cell carcinoma.
    Lucarelli G; Loizzo D; Franzin R; Battaglia S; Ferro M; Cantiello F; Castellano G; Bettocchi C; Ditonno P; Battaglia M
    Expert Rev Mol Diagn; 2019 May; 19(5):397-407. PubMed ID: 30983433
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Value of global metabolomics in association with diagnosis and clinicopathological factors of renal cell carcinoma.
    Sato T; Kawasaki Y; Maekawa M; Takasaki S; Saigusa D; Ota H; Shimada S; Yamashita S; Mitsuzuka K; Yamaguchi H; Ito A; Kinoshita K; Koshiba S; Mano N; Arai Y
    Int J Cancer; 2019 Jul; 145(2):484-493. PubMed ID: 30628065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renal Cell Carcinoma as a Metabolic Disease: An Update on Main Pathways, Potential Biomarkers, and Therapeutic Targets.
    di Meo NA; Lasorsa F; Rutigliano M; Loizzo D; Ferro M; Stella A; Bizzoca C; Vincenti L; Pandolfo SD; Autorino R; Crocetto F; Montanari E; Spilotros M; Battaglia M; Ditonno P; Lucarelli G
    Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent advances in lipidomics: Analytical and clinical perspectives.
    Sethi S; Brietzke E
    Prostaglandins Other Lipid Mediat; 2017 Jan; 128-129():8-16. PubMed ID: 28039059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolomics in renal cell carcinoma: From biomarker identification to pathomechanism insights.
    Chen YY; Hu HH; Wang YN; Liu JR; Liu HJ; Liu JL; Zhao YY
    Arch Biochem Biophys; 2020 Nov; 695():108623. PubMed ID: 33039388
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analytical approaches for lipidomics and its potential applications in neuropsychiatric disorders.
    Sethi S; Hayashi MA; Sussulini A; Tasic L; Brietzke E
    World J Biol Psychiatry; 2017 Oct; 18(7):506-520. PubMed ID: 26555297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification and validation of novel prognostic markers in Renal Cell Carcinoma.
    Rabjerg M
    Dan Med J; 2017 Oct; 64(10):. PubMed ID: 28975890
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Application of ex vivo (1)H NMR metabonomics to the characterization and possible detection of renal cell carcinoma metastases.
    Gao H; Dong B; Jia J; Zhu H; Diao C; Yan Z; Huang Y; Li X
    J Cancer Res Clin Oncol; 2012 May; 138(5):753-61. PubMed ID: 22258851
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of plasma lipid biomarkers for prostate cancer by lipidomics and bioinformatics.
    Zhou X; Mao J; Ai J; Deng Y; Roth MR; Pound C; Henegar J; Welti R; Bigler SA
    PLoS One; 2012; 7(11):e48889. PubMed ID: 23152813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolomics informs common patterns of molecular dysfunction across histologies of renal cell carcinoma.
    DiNatale RG; Sanchez A; Hakimi AA; Reznik E
    Urol Oncol; 2020 Oct; 38(10):755-762. PubMed ID: 31155438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Introduction to high throughput platforms in kidney cancer: Genomics, transcriptomics, and metabolomics urologic oncology: Seminars and original investigations.
    Hakimi AA
    Urol Oncol; 2020 Oct; 38(10):741. PubMed ID: 32753358
    [No Abstract]   [Full Text] [Related]  

  • 19. A pilot investigation of a urinary metabolic biomarker discovery in renal cell carcinoma.
    Zhang M; Liu X; Liu X; Li H; Sun W; Zhang Y
    Int Urol Nephrol; 2020 Mar; 52(3):437-446. PubMed ID: 31732842
    [TBL] [Abstract][Full Text] [Related]  

  • 20. UPLC-MS based urine untargeted metabolomic analyses to differentiate bladder cancer from renal cell carcinoma.
    Wang Z; Liu X; Liu X; Sun H; Guo Z; Zheng G; Zhang Y; Sun W
    BMC Cancer; 2019 Dec; 19(1):1195. PubMed ID: 31805976
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.